… mechanisms that underlie the efficacy of chemotherapy has the potential not only to enable
… that enhance the clinical effectiveness of immune checkpoint inhibitors (ICIs) relative to their …

… Yet, this meta-analysis established the definite benefit of IO-chemotherapy vs chemotherapy
in terms of PFS and ORR in the first line setting, which might serve as moderate surrogate …

… by the arrival of immune checkpoint inhibitors (ICIs), especially … as lymphocyte activation
gene 3 inhibitors, or could target various … The mechanism of action of standard chemotherapy is …

… Only programmed death ligand-1 positive-high cancers derive a significant OS benefit. In …
checkpoint inhibitors to chemotherapy may improve both OS compared with chemotherapy …

… -checkpoint inhibitor (ICI) with or without chemotherapy, as … from randomized studies with
chemotherapy as the common … , the combination of chemotherapy, first with pembrolizumab, …

… Tremendous progress has been achieved in the field of immune checkpoint inhibitors (…
chemotherapy was considered as immunosuppressive. It is now recognized that chemotherapy …

… these developments of immune-checkpoint inhibitors (ICIs), … or standard chemotherapy, for
platinum-based chemotherapy (… -on to platinum-based chemotherapy as a first-line treatment …

… chemotherapeutic agents on the immune system and the potential value of these different
types of chemotherapy as … groups of chemotherapy: topoisomerase inhibitors, antimicrotubule …

… of immune checkpoint inhibitors with chemotherapy … checkpoint inhibitors pembrolizumab
and atezolizumab have already been approved by the FDA in combination with chemotherapy …

… of immune-checkpoint inhibitors (ICIs) plus chemotherapy in patients … inhibitor plus
chemotherapy, 308 receiving PD-1 inhibitors plus chemotherapy, 563 receiving CTLA-4 inhibitors …